Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.In this episode, we discuss:Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBBHow new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injectionsHow early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effectsHow the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platformsCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank